These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32278043)

  • 1. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
    Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
    Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
    Al-Baradie RS
    Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
    Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
    Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in colorectal cancer.
    Le DT
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):22-24. PubMed ID: 29741500
    [No Abstract]   [Full Text] [Related]  

  • 7. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapy based on camelid nanobodies.
    Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
    Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized cancer vaccination in head and neck cancer.
    Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
    Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
    Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
    Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 18. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
    Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
    Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.